Actinic (Solar) Keratosis - Pipeline Review, H1 2020
Actinic (Solar) Keratosis - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2020, provides an overview of the Actinic (Solar) Keratosis (Dermatology) pipeline landscape.
An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Unknown stages are 1, 1, 5, 3 and 1 respectively.
Actinic (Solar) Keratosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2020, provides an overview of the Actinic (Solar) Keratosis (Dermatology) pipeline landscape.
An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Unknown stages are 1, 1, 5, 3 and 1 respectively.
Actinic (Solar) Keratosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Actinic (Solar) Keratosis - Overview
Actinic (Solar) Keratosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Actinic (Solar) Keratosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development
AmDerma Pharmaceuticals LLC
Athenex Inc
G&E Corp
Henderson Morley Plc (Inactive)
Laboratories Ojer Pharma SL
MedC Biopharma Ltd
Nanology LLC
Neonc Technologies Inc
Oncology Research International Ltd
Singh Biotechnology LLC
Vidac Pharma Ltd
Actinic (Solar) Keratosis - Drug Profiles
(digoxin + furosemide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDC-2040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORIL-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBT-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOR-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirbanibulin mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tuvatexib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Actinic (Solar) Keratosis - Dormant Projects
Actinic (Solar) Keratosis - Discontinued Products
Actinic (Solar) Keratosis - Product Development Milestones
Featured News & Press Releases
Mar 09, 2020: Athenex announces FDA acceptance for filing of U.S. NDA for tirbanibulin ointment in actinic keratosis
Mar 02, 2020: Athenex’s partner Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for tirbanibulin ointment in actinic keratosis
Oct 28, 2019: Athenex announces progress update from partner Almirall on Tirbanibulin Ointment
Mar 04, 2019: Athenex announces positive topline results from two phase III studies of KX2-391 ointment 1% featured in late breaker program at the 2019 American Academy of Dermatology Annual Meeting
Feb 25, 2019: Athenex to host conference call with key opinion leader following oral presentation of phase III results of KX2-391 ointment in the treatment of actinic keratosis at the American Academy of Dermatology Annual Meeting
Feb 04, 2019: Athenex announces late-breaking oral presentation of KX2-391 ointment in two phase III studies at the American Academy of Dermatology Annual Meeting
Dec 16, 2018: Vidac Pharma announce publication of peer reviewed article on VDA-1102 mechanism of action
Sep 18, 2018: DFB Soria completes a phase 2 clinical Trial of submicron particle Paclitaxel anhydrous ointment for actinic keratosis
Jul 26, 2018: Almirall announces that both phase III trials of KX2-391 for actinic keratosis achieved primary endpoint
Jul 26, 2018: Athenex Announces That Two Phase 3 Pivotal Efficacy Studies of KX2-391 in Actinic Keratosis Achieved Their Primary Endpoints
Jul 10, 2018: Vidac Pharma Announces Initiation of Phase 2b Clinical Trial of VDA-1102 Ointment in Patients with Actinic Keratosis
Feb 20, 2018: Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting
Feb 14, 2018: Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis
Dec 18, 2017: NanOlogy Announces First Patient Enrolled in a Pancreatic Cancer Phase II Clinical Trial of NanoPac Adding to Trials in Prostate and Ovarian Cancers
Nov 28, 2017: Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Actinic (Solar) Keratosis - Overview
Actinic (Solar) Keratosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Actinic (Solar) Keratosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development
AmDerma Pharmaceuticals LLC
Athenex Inc
G&E Corp
Henderson Morley Plc (Inactive)
Laboratories Ojer Pharma SL
MedC Biopharma Ltd
Nanology LLC
Neonc Technologies Inc
Oncology Research International Ltd
Singh Biotechnology LLC
Vidac Pharma Ltd
Actinic (Solar) Keratosis - Drug Profiles
(digoxin + furosemide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDC-2040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORIL-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBT-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOR-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirbanibulin mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tuvatexib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Actinic (Solar) Keratosis - Dormant Projects
Actinic (Solar) Keratosis - Discontinued Products
Actinic (Solar) Keratosis - Product Development Milestones
Featured News & Press Releases
Mar 09, 2020: Athenex announces FDA acceptance for filing of U.S. NDA for tirbanibulin ointment in actinic keratosis
Mar 02, 2020: Athenex’s partner Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for tirbanibulin ointment in actinic keratosis
Oct 28, 2019: Athenex announces progress update from partner Almirall on Tirbanibulin Ointment
Mar 04, 2019: Athenex announces positive topline results from two phase III studies of KX2-391 ointment 1% featured in late breaker program at the 2019 American Academy of Dermatology Annual Meeting
Feb 25, 2019: Athenex to host conference call with key opinion leader following oral presentation of phase III results of KX2-391 ointment in the treatment of actinic keratosis at the American Academy of Dermatology Annual Meeting
Feb 04, 2019: Athenex announces late-breaking oral presentation of KX2-391 ointment in two phase III studies at the American Academy of Dermatology Annual Meeting
Dec 16, 2018: Vidac Pharma announce publication of peer reviewed article on VDA-1102 mechanism of action
Sep 18, 2018: DFB Soria completes a phase 2 clinical Trial of submicron particle Paclitaxel anhydrous ointment for actinic keratosis
Jul 26, 2018: Almirall announces that both phase III trials of KX2-391 for actinic keratosis achieved primary endpoint
Jul 26, 2018: Athenex Announces That Two Phase 3 Pivotal Efficacy Studies of KX2-391 in Actinic Keratosis Achieved Their Primary Endpoints
Jul 10, 2018: Vidac Pharma Announces Initiation of Phase 2b Clinical Trial of VDA-1102 Ointment in Patients with Actinic Keratosis
Feb 20, 2018: Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting
Feb 14, 2018: Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis
Dec 18, 2017: NanOlogy Announces First Patient Enrolled in a Pancreatic Cancer Phase II Clinical Trial of NanoPac Adding to Trials in Prostate and Ovarian Cancers
Nov 28, 2017: Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Actinic (Solar) Keratosis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Actinic (Solar) Keratosis - Pipeline by AmDerma Pharmaceuticals LLC, H1 2020
Actinic (Solar) Keratosis - Pipeline by Athenex Inc, H1 2020
Actinic (Solar) Keratosis - Pipeline by G&E Corp, H1 2020
Actinic (Solar) Keratosis - Pipeline by Henderson Morley Plc (Inactive), H1 2020
Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma SL, H1 2020
Actinic (Solar) Keratosis - Pipeline by MedC Biopharma Ltd, H1 2020
Actinic (Solar) Keratosis - Pipeline by Nanology LLC, H1 2020
Actinic (Solar) Keratosis - Pipeline by Neonc Technologies Inc, H1 2020
Actinic (Solar) Keratosis - Pipeline by Oncology Research International Ltd, H1 2020
Actinic (Solar) Keratosis - Pipeline by Singh Biotechnology LLC, H1 2020
Actinic (Solar) Keratosis - Pipeline by Vidac Pharma Ltd, H1 2020
Actinic (Solar) Keratosis - Dormant Projects, H1 2020
Actinic (Solar) Keratosis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Actinic (Solar) Keratosis - Dormant Projects, H1 2020 (Contd..2), H1 2020
Actinic (Solar) Keratosis - Discontinued Products, H1 2020
Number of Products under Development for Actinic (Solar) Keratosis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Actinic (Solar) Keratosis - Pipeline by AmDerma Pharmaceuticals LLC, H1 2020
Actinic (Solar) Keratosis - Pipeline by Athenex Inc, H1 2020
Actinic (Solar) Keratosis - Pipeline by G&E Corp, H1 2020
Actinic (Solar) Keratosis - Pipeline by Henderson Morley Plc (Inactive), H1 2020
Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma SL, H1 2020
Actinic (Solar) Keratosis - Pipeline by MedC Biopharma Ltd, H1 2020
Actinic (Solar) Keratosis - Pipeline by Nanology LLC, H1 2020
Actinic (Solar) Keratosis - Pipeline by Neonc Technologies Inc, H1 2020
Actinic (Solar) Keratosis - Pipeline by Oncology Research International Ltd, H1 2020
Actinic (Solar) Keratosis - Pipeline by Singh Biotechnology LLC, H1 2020
Actinic (Solar) Keratosis - Pipeline by Vidac Pharma Ltd, H1 2020
Actinic (Solar) Keratosis - Dormant Projects, H1 2020
Actinic (Solar) Keratosis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Actinic (Solar) Keratosis - Dormant Projects, H1 2020 (Contd..2), H1 2020
Actinic (Solar) Keratosis - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Actinic (Solar) Keratosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
AmDerma Pharmaceuticals LLC
Athenex Inc
G&E Corp
Henderson Morley Plc (Inactive)
Laboratories Ojer Pharma SL
MedC Biopharma Ltd
Nanology LLC
Neonc Technologies Inc
Oncology Research International Ltd
Singh Biotechnology LLC
Vidac Pharma Ltd
Number of Products under Development for Actinic (Solar) Keratosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
AmDerma Pharmaceuticals LLC
Athenex Inc
G&E Corp
Henderson Morley Plc (Inactive)
Laboratories Ojer Pharma SL
MedC Biopharma Ltd
Nanology LLC
Neonc Technologies Inc
Oncology Research International Ltd
Singh Biotechnology LLC
Vidac Pharma Ltd
